In early stage PAH, where pulmonary vascular remodeling and metabolic shifts toward fatty acid synthesis and FAO are prominent, inhibitors of de novo lipogenesis such as ACLY antagonists (e.g., BMS-303141) hold particular promise. Here, ACLY is linked to pulmonary arterial hypertension.